DHEA
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Best used to replace confirmed low DHEA-S for neurosteroid tone, libido, mood/cognition, bone support, and downstream sex-hormone substrate.
DHEA should be lab-confirmed replacement, not blind hormone tinkering; DHEA-S baseline, sex-specific androgen/estrogen effects, and hormone-sensitive cancer history are the gates.
Best used to replace confirmed low DHEA-S for neurosteroid tone, libido, mood/cognition, bone support, and downstream sex-hormone substrate. It is not a general testosterone booster when baseline DHEA-S is normal.
Supraphysiologic dosing can drive acne, androgenic effects, estradiol elevation, bloating, and HDL pressure in women. Hormone-sensitive cancer is a hard stop, and starting without baseline DHEA-S testing is the main misuse pattern.
A cheap OTC oral option for restoring a measurable adrenal neurosteroid deficit. In TRT users, aging adults, postmenopausal women, and adrenal-insufficiency patients with confirmed low DHEA-S, it replaces a missing precursor; in users with normal DHEA-S, the article's own evidence points mostly to side effects and wasted money.
High in confirmed-deficient users, with cognition, libido, and mood reports often appearing within 2–4 weeks. Null in young healthy men and women with normal DHEA-S/adrenal function. The mature community verdict is bounded: DHEA is useful when deficiency is real, not as a speculative upgrade.
Intro
DHEA (dehydroepiandrosterone) is a 19-carbon steroid hormone synthesized primarily in the zona reticularis of the adrenal cortex.
It is the most abundant circulating steroid hormone in the human body and serves as the principal precursor for peripheral androgen and estrogen synthesis via the cholesterol → pregnenolone → DHEA → androstenedione → testosterone/estradiol pathway. DHEA circulates primarily as DHEA-S (sulfated form), which has a longer half-life and serves as the tissue-accessible reservoir for on-demand desulfation and local conversion. The Labrie intracrine model establishes that peripheral tissues — skin, breast, bone, brain, muscle — convert DHEA locally via tissue-specific 3β-HSD and 17β-HSD enzymes, meaning serum testosterone and estradiol do not accurately reflect tissue-level androgenic/estrogenic activity from DHEA.
DHEA and DHEA-S are also synthesized de novo in the brain, classifying them as neurosteroids with direct CNS receptor activity — GPCR (endothelial), GABAa (anxiolytic/sleep), NMDA (pro-cognitive/neuroprotective), sigma-1 (antidepressant), GPER1, CAR, PPARα, TRPM3, and voltage-gated Na+/Ca2+ channels. These direct receptor mechanisms underpin the rapid cognitive and mood effects (1–2 weeks) that appear faster than any downstream hormone conversion could account for.
DHEA-S peaks at ages 20–25 then declines ~2–3% per year — one of the most consistent endocrine changes in human aging. Adrenal DHEA output is HPA-dependent (ACTH-driven), not HPG-dependent. HCG, which acts on LH receptors in Leydig cells, has no effect on adrenal DHEA-S. Chronic stress creates pregnenolone steal — elevated cortisol demand monopolizes pregnenolone, reducing DHEA synthesis — explaining low DHEA-S in high-stress contexts without true adrenal insufficiency.
Critical product distinctions: 7-keto DHEA is a downstream metabolite that cannot convert back to DHEA, testosterone, or estradiol (thermogenic effects only; not interchangeable). Wild yam extract does not provide bioactive DHEA — the human body cannot convert diosgenin to DHEA; only industrial synthesis does that. Synthetic DHEA is manufactured from diosgenin but requires industrial chemical processing.
Observed Effects
Sex hormone elevation in postmenopausal women is the best-supported primary effect: meta-analysis of 21 RCTs found testosterone WMD +24.31 ng/dL (95% CI 15.22–33.40) and estradiol WMD +7.86 pg/mL (95% CI 6.33–9.40) at ≥50 mg/day, with larger effects in women ≥60 years. Health-related quality of life and depression improvement in adrenal insufficiency is the second-most replicated finding: JCEM 2009 meta-analysis (10 trials, n=264) found HRQOL effect size 0.21 (95% CI 0.08–0.33) with consistent depression improvement. Lean body mass increase is statistically significant in meta-analysis but effect size is modest without concurrent changes in body weight, BMI, or blood pressure. BMD improvement in elderly women (≥70) was demonstrated in the DHEAge RCT (50 mg/day × 12 months, n=280).
In community populations with confirmed low DHEA-S, libido and erectile function restoration in men is described as dramatic — 'completely changed my libido,' 'nocturnal erections returned after years' — with onset within 2–4 weeks. Cognitive clarity and reduced brain fog emerge within 1–2 weeks, attributed to neurosteroid CNS mechanisms rather than downstream hormone conversion. Sleep quality improvement with DHEA + pregnenolone combination is consistently reported, attributed to GABAa and neurosteroid REM modulation. AMH improvement in women with diminished ovarian reserve is a strong community finding (one widely-cited case: AMH 2.1 → 10.75 pmol/L on 75 mg/day × 6 months) with small RCT support.
Null results: no significant libido improvement in women with normal adrenal function (Elraiyah 2014, n=1,188, SMD 0.35, P=0.06); no meaningful testosterone elevation in young healthy men with normal DHEA-S; no significant effect on body weight, BMI, blood pressure, total cholesterol, LDL, or triglycerides in meta-analysis; no reliable improvement in strength or physical performance in healthy older adults (DHEA-2 trial); IGF-1 increase modest and not clinically meaningful for GH axis optimization. The recurring pattern: DHEA produces clear, measurable benefits in confirmed-deficient populations and essentially no benefit in those with normal baseline levels.
Field Reports
Positive experiences in confirmed-deficient users are among the most consistently compelling in the TRT and hormone optimization community.
Libido and erectile function restoration in men with documented low DHEA-S is described as dramatic — 'completely changed my libido,' 'nocturnal erections returned after years,' 'felt like testosterone therapy without being on testosterone.' Onset within 2–4 weeks. Cognitive clarity and reduced brain fog with 1–2 week onset is 'insane for cognitive benefit' in deficient users — faster onset than sex hormone conversion effects suggests direct neurosteroid CNS activity. Sleep quality improvement with DHEA + pregnenolone combination is near-universally reported by TRT users — more vivid dreams, faster onset, more rested; the effect is often apparent within the first week.
Fertility community experiences with AMH improvement and IVF outcomes in women with diminished ovarian reserve are among the strongest application-specific reports. The Gleicher/Barad protocol has been adopted by fertility care; community case reports of dramatic AMH improvement are widely circulated.
Negative experiences cluster around dose-related androgenic and estrogenic side effects in users who started at 50 mg without baseline testing. The pattern is near-universal: feeling good for 1–2 weeks, then progressive acne, oily skin, and bloating by weeks 2–3, followed by stopping DHEA entirely and concluding it 'doesn't work' or 'caused problems.' The dose, not the compound, is the issue. Most community members who experienced side effects resolved them with dose reduction rather than discontinuation.
Adrenal insufficiency patients on long-term DHEA often find attempts to stop result in severe depression and fatigue returning within 2–4 weeks — not pharmacological withdrawal but symptom relapse. The community distinguishes this clearly from TRT users without true adrenal insufficiency.
Community Consensus
The TRT and hormone-optimization community frames DHEA primarily as hormonal cascade backfill: testosterone can normalize while DHEA-S remains low, leaving a neurosteroid gap that testosterone alone does not replace.
DHEA + pregnenolone is the standard community pairing. The mature position is explicit: DHEA is only meaningful when baseline DHEA-S is confirmed low.
The most-cited clinical dosing reference is the Rouzier weight-based framework: men <200 lb = 50 mg AM; men >200 lb = 75–100 mg AM; women <50 yo = 10–15 mg AM; women >50 yo = 25 mg AM. Optimal DHEA-S targets: men 500–600 μg/dL, women 200–250 μg/dL. Monitor monthly until stable.
Women are viewed as particularly underserved because adrenal DHEA becomes a more important androgen source after menopause. The null-result data from studies in women with normal adrenal function should not be generalized to women with adrenal insufficiency, low DHEA-S, or postmenopausal deficiency patterns.
Active community debates include sublingual vs. oral vs. transdermal administration; scrotal transdermal DHEA for higher androgen conversion (experimental, no RCT support); DHEA + progesterone vs. DHEA + pregnenolone pairing; and whether DHEA-S monitoring can be reduced once a stable dose is established.
Risks & Monitoring
Acne and oily skin is the most consistent side effect across all user reports — mechanism is DHEA → androstenedione → DHT conversion in sebaceous glands via 3β-HSD and 5-alpha reductase.
Dose-dependent: almost universal at 50–100 mg/day in non-deficient individuals, manageable at 10–25 mg/day in most users. Resolves with dose reduction in the majority of cases. Women have higher peripheral 3β-HSD activity for DHEA → androgen conversion, making acne and oily skin more pronounced at a given dose.
Bloating and water retention from E2 conversion is common at 50 mg+ in men without confirmed deficiency. The DHEA-S reservoir mechanism explains the delayed onset — DHEA-S builds over 2–3 weeks after starting, then drives sustained aromatization. Pattern: 'felt great week 1, bloated and emotional by week 3.' Managed with dose reduction; DIM (diindolylmethane) for mild cases; low-dose AI for persistent estrogenic side effects. Breast tenderness in women is reported as a dose-related estrogenic effect.
HDL reduction is the primary cardiovascular safety signal — meta-analysis shows significant HDL decrease in women but not men, attributed to greater peripheral androgenic conversion from DHEA in women. No significant effect on systolic/diastolic blood pressure, total cholesterol, LDL, or triglycerides in RCTs. Hair thinning/shedding at higher doses is DHT-mediated in genetically susceptible individuals; initial shedding often normalizes over time.
The DHEAge Study (50 mg/day × 12 months, n=280 adults aged 60–79) found no significant adverse cardiovascular effects and no significant changes in sex hormone-sensitive tissues (prostate, breast, uterine). Trenbolone use is community-associated with persistently low DHEA-S for 12+ months post-PCT despite testosterone recovery — attributed to trenbolone's glucocorticoid receptor activity and potential zona reticularis damage; this is a community observation without confirmed clinical research. Adrenal insufficiency patients experience symptom relapse (depression, fatigue, cognitive decline) when DHEA is stopped — this is biological replacement need, not pharmacological withdrawal.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Single non-negotiable pre-supplementation requirement. Determines whether supplementation is indicated. Men: deficiency threshold generally <200 μg/dL functional, optimal target 400–600 μg/dL. Women: deficiency threshold generally <80 μg/dL functional, optimal target 200–250 μg/dL. DHEA-S (not DHEA) is used because of its longer half-life and greater measurement stability.
Retest at 6–8 weeks after starting. DHEA-S levels typically stabilize by week 4–6. Titrate dose to achieve optimal target range. If DHEA-S is in upper range or above target, reduce dose. Ongoing monitoring every 3–6 months at steady state.
HDL reduction is the primary cardiovascular safety signal for DHEA in women. Establish baseline HDL before starting. Monitor at 3–6 months in women, particularly at ≥50 mg/day. No significant effect on LDL or total cholesterol in RCTs, but HDL reduction in women warrants monitoring.
Tracks androgenic and estrogenic conversion. Most relevant in women post-menopause where DHEA is primary androgen precursor. Serum testosterone elevation in men from oral DHEA is modest due to intracrine conversion. Estradiol elevation drives bloating and mood side effects; dose reduction indicated if estradiol rises outside comfortable range.
Useful when low DHEA-S may reflect pregnenolone steal from chronic stress rather than true adrenal insufficiency. Cortisol:DHEA-S ratio >5:1 suggests HPA dysregulation. Addressing the stressor may normalize DHEA-S without supplementation in these cases.
Baseline PSA before starting DHEA in men over 50 given androgenic conversion. Active or high-risk prostate cancer is a contraindication.
Avoid With
Do not combine DHEA with the following. Sorted highest-severity first.
Why:DHEA converts peripherally to testosterone and estradiol — androgenic and estrogenic stimulation of hormone-sensitive tumors is a real risk
What to do:Absolute contraindication in active hormone-sensitive cancers. Consult oncologist before any DHEA use in cancer history.
Why:Excessive AI use drives DHEA conversion toward androgenic pathways (blocked aromatase → more DHT conversion) and eliminates the estrogenic CNS benefits of DHEA. Low-dose AI to manage excessive E2 conversion is clinically appropriate; aggressive AI elimination of all estrogen negates DHEA's mood and neurosteroid benefits.
What to do:Not a contraindication at low AI doses for E2 management — only aggressive E2 suppression negates DHEA benefit
Why:Trenbolone's potent glucocorticoid receptor activity and HPA suppression may persistently reduce adrenal DHEA output. Community reports document low DHEA-S lasting 12+ months post-trenbolone PCT despite gonadal testosterone recovery.
What to do:Not a stack contraindication — DHEA supplementation is warranted post-trenbolone in users with confirmed low DHEA-S; monitor recovery timeline carefully
Why:DHEA supplementation improves insulin sensitivity in adrenal insufficiency. Concurrent use with insulin secretagogues or insulin in diabetic patients may require glucose monitoring adjustments.
What to do:Relevant primarily in adrenal insufficiency patients with concurrent diabetes; not a significant interaction in general use
Protocols By Goal
TRT neurosteroid backfill: DHEA 25–50 mg/day + pregnenolone 10–25 mg/day, morning, throughout TRT cycle.
Rationale: exogenous testosterone suppresses adrenal DHEA output via HPA/HPG coupling; the neurosteroid deficit is not replaced by testosterone alone. Monitor DHEA-S at 6–8 weeks; target 400–600 μg/dL men.
Postmenopausal hormone support: 25–50 mg/day oral, morning; titrate to DHEA-S target 200–250 μg/dL. Strongest single use case supported by meta-analysis — DHEA at ≥50 mg/day reliably elevates testosterone (WMD +24.31 ng/dL) and estradiol (WMD +7.86 pg/mL) in postmenopausal women. Monitor HDL at 3 months — HDL reduction is the primary safety signal in women.
Adrenal insufficiency replacement: 50 mg/day oral, morning; titrate to age-appropriate DHEA-S target; monitor indefinitely — these patients often cannot stop DHEA without symptom relapse. HRQOL improvement (ES 0.21), depression improvement, insulin sensitivity improvement, BMD preservation, and immune cell normalization are documented in RCTs.
IVF/diminished ovarian reserve: Gleicher/Barad protocol — 75 mg/day for 2–6 months before egg retrieval; coordinate with fertility physician. Monitor AMH and antral follicle count at 3-month intervals.
Dosing Details
Standard protocol: men 25–50 mg/day oral, morning. Start at 25 mg if DHEA-S is modestly low; use 50 mg if severely depressed.
Rouzier framework: men <200 lb = 50 mg AM; men >200 lb = 75–100 mg AM in anti-aging/replacement context. TRT backfill context: 25–50 mg/day regardless of weight. Women: 10–25 mg/day oral, morning. Start at 10 mg; increase to 25 mg if DHEA-S remains below target at 6–8 weeks. Rouzier framework: women <50 yo = 10–15 mg AM; women >50 yo = 25 mg AM. IVF/fertility protocols: 25–75 mg/day for 2–6 months before egg retrieval.
TRT neurosteroid backfill: 25–50 mg/day DHEA + 10–25 mg/day pregnenolone, taken together in the morning, throughout TRT cycle. HCG does not substitute — adrenal DHEA production is HPA-dependent, not HPG-dependent. DHEAge anti-aging anchor: 50 mg/day oral is the most extensively studied dose in elderly subjects (12 months, 280 adults 60–79, well-tolerated). Titrate based on DHEA-S monitoring at 6–8 weeks rather than using a fixed dose indefinitely.
Monitoring targets: men DHEA-S 400–600 μg/dL, women DHEA-S 200–250 μg/dL. Retest at 6–8 weeks, then every 3–6 months at steady state. Cautionary anchor: starting at 50–100 mg without baseline testing is the most common error — the pattern is 2–3 weeks of improved wellbeing → mounting acne, bloating, mood swings → stopping DHEA and blaming the compound. The dose, not the compound, is at fault.
Stacks & Alternatives
The near-universal pairing in TRT and hormone optimization communities. Pregnenolone is the upstream precursor (cholesterol → pregnenolone → DHEA) with its own independent neurosteroid effects — memory, neuroprotection, NMDA modulation. Supplementing both covers the cascade from two points. The combination produces the sleep quality improvement and vivid dream restoration reported by TRT users, attributed to combined GABAa and neurosteroid REM modulation. Stacking HCG + DHEA/pregnenolone provides complementary coverage: HCG supports gonadal steroidogenesis (testicular), DHEA/pregnenolone supports adrenal neurosteroid supply. Both taken together in the morning.
Optional co-administration for users experiencing estrogenic side effects (bloating, mood changes, breast tenderness) from DHEA's peripheral aromatization. DIM modulates estrogen metabolism toward 2-hydroxyestrone (less estrogenic) pathway rather than the 16-alpha pathway. Preferred as a first intervention over AI, which eliminates E2 entirely and negates DHEA's neurosteroid/estrogenic CNS benefits.
Favored in the Ray Peat bioenergetics community as an alternative to DIM. Progesterone inhibits aromatase and 5-alpha reductase, theoretically steering DHEA conversion toward DHT rather than estrone. Less mainstream than DHEA/pregnenolone pairing; community/biohacking evidence only — no RCT data on this specific combination.
Alternatives
Stack Cost
A low-tax replacement supplement — one morning capsule, simple monitoring, no injection, no PCT — but only appropriate when DHEA-S is confirmed low; without baseline testing, androgenic and estrogenic side effects shift the tax to moderate.
Baseline DHEA-S required (one-time or periodic). Retest at 6–8 weeks, then every 3–6 months at steady state. Lipid panel (HDL) recommended in women. No daily monitoring required. Lower burden than any injectable or suppressive compound.
Dose-dependent androgenic (acne, oily skin, DHT-mediated hair) and estrogenic (bloating, mood) side effects when started without baseline or at supraphysiologic doses. Fully reversible with dose reduction. Side effects are predictable and manageable — they indicate dose overshoot, not compound toxicity.
WADA-banned substance — full disqualification risk for tested competitive athletes. This is the only high-tax driver for DHEA and applies only to athletes in tested sports.
- ·No concurrent AAS required — DHEA is an OTC oral compound not a suppressive compound
- ·At 50 mg+ in non-deficient users: consider adding DIM before reaching for an AI to manage E2 conversion
- ·Post-trenbolone users may need extended DHEA supplementation beyond standard PCT timelines
- ·DIM (optional, for E2 conversion management at 50 mg+)
- ·Pregnenolone (commonly co-stacked for full neurosteroid cascade coverage)
Lab-confirmed deficiency + OTC oral once-daily morning dosing + simple monitoring = lowest possible onboarding burden. The only barrier is the baseline DHEA-S test requirement, which is a healthcare-system hurdle, not a compound-complexity hurdle.
- ·Wants to add DHEA speculatively without baseline testing — side effects are predictable and blame-redirected
- ·Active hormone-sensitive cancer or high-risk prostate condition
- ·Competitive athlete in a tested sport (WADA ban is an absolute barrier)
Can be stopped at any time in non-adrenal insufficiency patients without significant withdrawal. Adrenal insufficiency patients experience symptom relapse (not pharmacological withdrawal) and should taper or consult a physician before stopping. No HPG axis recovery protocol required.
- ·Adrenal insufficiency patients: symptom relapse (depression, fatigue, cognitive decline) within 2–4 weeks — biological replacement need, not addiction
- ·Long-term users (non-AI): gradual dose reduction over 4–8 weeks is prudent to allow adrenal production to normalize
Test DHEA-S before starting. If deficient, dose appropriately (25 mg in men as starting point). If side effects appear despite correct dosing, reduce dose by 50% and reassess at 6 weeks.
Check baseline DHEA-S. If normal, discontinue — there is no established benefit pathway for DHEA in non-deficient young men.
Verify product contains synthetic DHEA. Check label for 'DHEA' or 'dehydroepiandrosterone' as the active ingredient, not 'wild yam extract' or '7-keto DHEA.'
Monitor DHEA-S on TRT even when using HCG. HCG acts on Leydig cells (HPG axis), not adrenal cortex (HPA axis). Exogenous DHEA is required.
DHEA converts peripherally to testosterone and estradiol — androgenic/estrogenic stimulation of hormone-sensitive tumors
DHEA is on the WADA prohibited list as an anabolic steroid precursor — any DHEA use risks disqualification and sanctions
DHT-mediated androgenic conversion — dose is likely above the user's conversion threshold; dose reduction, not continuation at current dose
Primary cardiovascular safety signal in women on DHEA — androgenic conversion reduces HDL in women more than men
Practical Setup
Before starting: test DHEA-S — non-negotiable. If in normal range for age, supplementation is unlikely to produce benefit and will produce androgenic/estrogenic side effects.
Evaluate whether low DHEA-S reflects true adrenal insufficiency or pregnenolone steal from chronic stress (cortisol:DHEA-S ratio >5:1 suggests stress-driven HPA dysregulation — lifestyle intervention may normalize without supplementation). Establish baseline lipids (HDL in women) and PSA (men 50+). Confirm no hormone-sensitive cancers or active prostate conditions.
During supplementation: retest DHEA-S at 6–8 weeks; titrate dose to target range rather than staying at a fixed dose. Monitor for androgenic side effects (acne, oily skin, hair changes) — reduce by 50% before abandoning the compound. Monitor for estrogenic effects (bloating, mood changes) — dose reduction is cleaner than reaching for an AI. HCG does not raise DHEA-S; if using HCG for testicular preservation on TRT, still need exogenous DHEA.
Product selection: OTC standard capsules adequate for most users; micronized/slow-release compounded formulations reduce conversion spikes and are preferred at 50 mg+. Sublingual increases bioavailability but produces a sharp peak — some find this more androgenically stimulating than intended. Avoid products labeled 'wild yam extract' or 'natural DHEA' without confirmed synthetic DHEA content — diosgenin cannot be converted to DHEA by the human body. 7-keto DHEA products are not DHEA — wrong product for hormonal or neurosteroid goals regardless of marketing claims.
Post-trenbolone note: DHEA-S may remain suppressed for 12+ months after trenbolone use even after testosterone recovery. Test at PCT completion and at 3-month intervals post-cycle. If persistently low, DHEA supplementation may be required longer than standard PCT.
Mechanism Deep Dive
Intracrine precursor conversion (Labrie model): DHEA-S is released from the adrenal gland into circulation, desulfated by steroid sulfatase in peripheral tissues, then converted locally to active androgens and estrogens via tissue-specific 3β-HSD and 17β-HSD. This intracrine system means circulating testosterone and estradiol do NOT accurately reflect tissue-level androgenic/estrogenic activity from DHEA — tissue concentrations are controlled by local enzyme expression and are largely invisible to serum measurements. This explains why DHEA supplementation can produce marked symptom improvement without proportional serum testosterone elevation.
Direct receptor signaling independent of intracrine conversion: DHEA acts as a direct ligand at multiple non-classical receptors — GPCR on endothelial cells (vasorelaxation), GABAa receptor (anxiolytic, sleep modulation), NMDA receptor (pro-cognitive, neuroprotective), sigma-1 receptor (antidepressant, anti-anxiety), GPER1 (membrane estrogen receptor), constitutive androstane receptor (CAR), PPARα (metabolic effects via indirect dephosphorylation), TRPM3 via the DHEA-2 metabolite, and voltage-gated Na+/Ca2+ channels. These direct receptor effects explain the rapid CNS benefits (mood, cognition, sleep) that appear within 1–2 weeks — faster than sex hormone conversion effects — and cardiovascular benefits observed without significant serum sex hormone changes.
Pharmacokinetics: DHEA itself has a short plasma half-life (~25 minutes to 1–2 hours). DHEA-S has a much longer half-life (7–10 hours) and functions as a circulating reservoir — DHEA is rapidly sulfated after absorption, stored as DHEA-S, then desulfated on demand in peripheral tissues. This explains: (1) once-daily dosing is functionally sufficient despite DHEA's short plasma half-life; (2) side effects can emerge 2–3 weeks after starting as the DHEA-S reservoir fills; (3) serum DHEA-S, not DHEA, is the appropriate monitoring target. DHEA-S behaves like a temporary reservoir: the sulfate group keeps the hormone inactive until tissues convert it back on demand.
Adrenal decline and HPA independence: DHEA-S peaks at ages 20–25, declines ~2–3% per year, reaching ~80% below peak by age 75. Adrenal DHEA production is ACTH-driven (HPA axis); HCG, which stimulates LH receptors in Leydig cells, has no effect on adrenal DHEA output — 'the adrenal gland didn't really respond' to HCG. Pregnenolone steal: elevated cortisol demand from chronic stress redirects pregnenolone away from DHEA synthesis, explaining low DHEA-S in high-stress contexts with preserved or elevated cortisol.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
DHEA at ≥50 mg/day increases testosterone WMD +24.31 ng/dL and estradiol WMD +7.86 pg/mL
Springer 2025 meta-analysis of 21 RCT arms in postmenopausal women. Effects specific to this population — do not generalize to premenopausal women or men.
DHEA does not significantly improve libido in women with normal adrenal function — SMD 0.35, P=0.06
Elraiyah Mayo Clinic systematic review. Critical population modifier: normal adrenal function. Contrast with adrenal insufficiency populations where wellbeing improves.
DHEA produces HRQOL improvement effect size 0.21 in adrenal insufficiency
JCEM 2009 meta-analysis of 10 trials (3–12 months). Depression improvement most consistent finding. Sexual wellbeing not statistically significant.
DHEAge: 50 mg/day oral DHEA for 12 months produced DHEA-S normalization, sex hormone elevation in women, and BMD improvement with no significant adverse effects
Baulieu et al. PNAS 2000. Primary long-term safety reference for 50 mg/day in elderly. BMD improvement particularly in women >70.
HDL reduction with DHEA supplementation seen in women but not men
ScienceDirect 2020 meta-analysis (Nutrition, Metabolism and Cardiovascular Diseases). Primary cardiovascular safety signal for women on DHEA.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.